Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER

References

• Leucht S, Wahlbeck K, Hamann J, , et al. . New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-9
   PubMed Web of Science ®Google Scholar
• Robinson D, Woerner MG, Alvir JM, , et al. . Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-7
   PubMed Web of Science ®Google Scholar
• Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 2006;67(Suppl 5):3-8
   PubMed Web of Science ®Google Scholar
• Hamann J, Mischo C, Langer B, , et al. . Physicians' and patients' involvement in relapse prevention with antipsychotics in schizophrenia. Psychiatr Serv 2005;56:1448-50
   PubMed Web of Science ®Google Scholar
• Surles RC. Atypical antipsychotics: considerations for Medicaid coverage. Am J Manag Care 2005;11(8 Suppl):S248-S53
   Google Scholar
• Vazquez-Polo FJ, Negrin M, Cabases JM, , et al. . An analysis of the costs of treating schizophrenia in Spain: a hierarchical Bayesian approach. J Ment Health Policy Econ 2005;8:153-65
   PubMed Web of Science ®Google Scholar
• Almond S, Knapp M, Francois C, , et al. . Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004;184:346-51
   PubMed Web of Science ®Google Scholar
• Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004;30:279-93
   PubMed Web of Science ®Google Scholar
• Blomqvist AG, Leger PT, Hoch JS. The cost of schizophrenia: lessons from an international comparison. J Ment Health Policy Econ 2006;9:177-83
   PubMed Web of Science ®Google Scholar
• Wu E, Birnbaum H, Shi L, , et al. . Economic burden of schizophrenia in 2002. J Clin Psychiatry 2005;66:1122-9
   PubMed Web of Science ®Google Scholar
• Leucht S, Heres S, Hamann J, , et al. . Methodological issues in current antipsychotic drug trials. Schizophr Bull 2008;34:275-85
   PubMed Web of Science ®Google Scholar
• Burns T, Fiander M, Audini B. A delphi approach to characterising ‘relapse’ as used in UK clinical practice. Int J Soc Psychiatry 2000;46:220
   PubMed Web of Science ®Google Scholar
• Nuechterlein K, Miklowitz DJ, Ventura J, , et al. . Classifying episodes in schizophrenia and bipolar disorder: criteria for relapse and remission applied to recent-onset samples. Psychiatry Res 2006;144:153-66
   PubMed Web of Science ®Google Scholar
• Peuskens P, Trivedi JK, Malyarov S, , et al. . Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized placebo-controlled trial in clinically stable patients. Psychiatry (Edgemont) 2007;4:34-50
   PubMedGoogle Scholar
• Kramer M, Simpson G, Maciulis V, , et al. . Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007;27:6-14
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Sutton VK, Hamilton SH, , et al. . A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 2003;23:582-94
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. National Statistics Online: Population, National Projections, UK, 2006. http://www.statistics.gov.uk/cci/nugget.asp?id=1352 [Last accessed Nov 26 2007]
   Google Scholar
• Office for National Statistics. Key Health Statistics from General Practice 1996, Series MB6, No. 1 (London: 1998).http://www.statistics.gov.uk/STAYBASE/Product. asp?vlnk=4912&More=Y [Last accessed Nov 28 2007]
   Google Scholar
• Saha S, Chant D, Welham J, , et al. . A systematic review of the prevalence of schizophrenia. PLoS Med 2005;2:e141
   PubMed Web of Science ®Google Scholar
• Curtis L, Netten A. Unit costs of health and social care. University of Kent Personal Social Services Research: Canterbury, Kent, 2006/2007
   Google Scholar
• Dossenbach M, Arango-Davila C, Silva Ibarra H, , et al. . Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 2005;66:1021-30
   PubMed Web of Science ®Google Scholar
• Heres S, Davis J, Maino K, , et al. . Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006;163:185-94
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Carpenter WT Jr, Kane JM, , et al. . Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-9
   PubMed Web of Science ®Google Scholar
• Pecenak J. Relapse prevention in schizophrenia: evidence from longterm, randomized, double-blind clinical trials. Neuro Endocrinol Lett. 2007;28:49-70
   PubMed Web of Science ®Google Scholar
• Leucht S, Barnes TRE, Kissling W, , et al. . Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-22
   PubMed Web of Science ®Google Scholar